Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol.

Acitretin has recently been introduced to replace etretinate in the treatment of severe psoriasis due to a considerable shorter terminal half-life. The previously recommended 2-month anticonceptive period after acitretin treatment has been extended to 2 years after the detection of etretinate in certain acitretin recipients. In the present study, 10 patients with severe psoriasis were treated with 30 mg acitretin daily for 3 months. Seven patients had detectable mean steady-state plasma etretinate concentrations in the range of 2.5 to 56.7 ng/ml. Four of the patients showed teratogenic levels of plasma etretinate. Consumption of alcohol appeared to be an important contributing factor for the formation of etretinate. As judged from the dose- and body-weight-normalized AUC values (AUCcor) there was a great inter-individual variation (sixfold) in the systemic availability of acitretin. After discontinuation of therapy, the rate of elimination of both acitretin (t1/2 range 1.0 to 25.4 d) and 13-cis-acitretin (t1/2 range 1.5 to 25.7 d) was found to be related to the observed mean steady-state level of etretinate as evidenced by a longer terminal t1/2 of patients with high levels of etretinate in plasma. A mean terminal elimination half-life of etretinate was found to be 45.7 d +/- 10.6 (mean +/- SD; range 27.0 to 59.3 d). The risk of metabolic formation of etretinate in acitretin recipients makes it impossible to draw any definite conclusion with regard to recommendation of length of anticonceptive period following acitretin therapy in psoriatics. Monitoring of plasma etretinate levels in acitretin-treated fertile women is advisable.

[1]  B. Jensen,et al.  Pharmacokinetics of Acitretin in Humans , 1991 .

[2]  F. G. Larsen,et al.  The Pharmacokinetics of Acitretin and its 13‐cis‐metabolite in Psoriatic Patients , 1991, Journal of clinical pharmacology.

[3]  H. Gollnick,et al.  Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. , 1988, Journal of the American Academy of Dermatology.

[4]  F. G. Larsen,et al.  Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. , 1988, Pharmacology & toxicology.

[5]  H. DeLuca,et al.  Activation of retinoic acid by coenzyme A for the formation of ethyl retinoate. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[6]  W. Colburn,et al.  Etretinate kinetics during chronic dosing in severe psoriasis , 1985, Clinical pharmacology and therapeutics.

[7]  S. Jabłońska,et al.  Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis. , 1983, Journal of the American Academy of Dermatology.

[8]  A. Vahlquist,et al.  Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate * , 1983, The British journal of dermatology.

[9]  K. Stöckel,et al.  ON METABOLISM AND PHARMACOKINETICS OF AN AROMATIC RETINOID , 1981, Annals of the New York Academy of Sciences.

[10]  J. Mørland,et al.  Ethanol-induced increase in drug acetylation in man and isolated rat liver cells. , 1978, British medical journal.

[11]  G. Englert,et al.  Der Metabolismus des Retinoids Ro 10-9359. Isolierung und Identifizierung der Hauptmetaboliten aus Plasma, Urin und Faeces des Menschen sowie aus der Galle der Ratte Synthese von drei Urinmetaboliten , 1977 .

[12]  W. Bollag.  Prophylaxis of chemically induced epithelial tumors with an aromatic retinoic acid analog (Ro 10-9359). , 1975, European journal of cancer.

[13]  W. Bollag,et al.  [Treatment of psoriasis with an orally administered effective new vitamin A acid derivative. Preliminary report]. , 1975, Schweizerische medizinische Wochenschrift.

[14]  W. Bollag.  Therapeutic effects of an aromatic retinoic acid analog on chemically induced skin papillomas and carcinomas of mice. , 1974, European journal of cancer.

[15]  C. Huselton,et al.  A newly discovered xenobiotic metabolic pathway: ethyl ester formation. , 1991, Life sciences.

[16]  H. Nau,et al.  Teratogenicity of steady-state concentrations of etretinate and metabolite acitretin maintained in maternal plasma and embryo by intragastric infusion during organogenesis in the mouse: a possible model for the extended elimination phase in human therapy. , 1990, Developmental pharmacology and therapeutics.

[17]  Brindley Cj.  Overview of Recent Clinical Pharmacokinetic Studies with Acitretin (Ro 10-1670, Etretin) , 1989 .

[18]  F. G. Larsen,et al.  Simultaneous determination of the aromatic retinoids etretin and etretinate and their main metabolites by reversed-phase liquid chromatography. , 1987, Journal of chromatography.

[19]  A. Vahlquist,et al.  Tissue distribution of aromatic retinoid (etretinate) in three autopsy cases: drug accumulation in adrenals and fat. , 1986, Acta dermato-venereologica.

[20]  W. Bollag.  New Retinoids with Potential Use in Humans , 1985 .

[21]  T. Lóránd,et al.  Treatment of generalized pustular psoriasis with Ro-10-9359. , 1983, Dermatologica.

[22]  R. Hänni.  Pharmacokinetic and metabolic pathways of systemically applied retinoids. , 1978, Dermatologica.